Plasma GFAP can potentially be used to determine amyloid‐related pathology in prodromal stages of DLB, whereas p‐tau‐181 appears to be the most optimal plasma biomarker to detect both Aβ and tau pathologies at DLB. The gene discussed is MAPT; the disease is Lewy body dementia.